Asthma
Conference Coverage
Managing asthma in children: Pets don’t always have to go
SAN ANTONIO – Make sure guidelines are being closely followed before telling parents to consider getting rid of the family pet.
Conference Coverage
Reducing asthma, COPD exacerbations in obese patients
SAN ANTONIO - Obese patients with asthma or COPD typically have metabolic and inflammatory profiles that differ from those of nonobese patients...
Conference Coverage
Dupilumab efficacy extends to chronic rhinosinusitis/nasal polyposis
PARIS – Post hoc analysis of phase 3 trial data looked at the efficacy dupilumab in preventing asthma exacerbations in patients with chronic...
Feature
Alabama, Oregon, and pediatric asthma
The two states occupy opposite ends of the prevalence scale.
From the Journals
Community-based therapy improved asthma outcomes in African American teens
A home- and community-based, individualized behavioral treatment significantly improved outcomes in African American teens with poorly controlled...
News
Asthma medication ratio identifies high-risk pediatric patients
ATLANTA – A quality metric for asthma exacerbation could be lead to a helpful app.
From the Journals
New guidance offered for managing poorly controlled asthma in children
A practical resource for starting or adjusting controller therapy in children with poorly-controlled asthma now is available.
From the Journals
FDA reverses warning on LABA-containing asthma medications
Four trials testing outcomes for patients taking the combination therapy.
From the Journals
Dupilumab reduces exacerbations, cuts glucocorticoid use in moderate to severe asthma
Evidence of lung remodeling was observed in patients with severe asthma in a trial of a anti–interleukin-4 alpha antibody drug.
From the Journals
Pediatric asthma patients should be considered priority for flu vaccine
Identifying pathogens in ED may be key to reducing treatment failure.
From the Journals
As-needed budesonide-formoterol prevented exacerbations in mild asthma
The regimen topped terbutaline and was noninferior to twice-daily budesonide.